Subchronic oral toxicity study of Rajat Bhasma (RB) and green synthesized silver nanoparticles (AgNPs)

Articles in Press

Document Type : Research Paper

Authors

1 Department of Rasashastra and Bhaishjya Kalpana, Govt. Ayurved College, Nanded, Maharashtra

2 Principal, Bhausaheb Mulak College of Pharmacy, Umred, Nagpur, Maharashtra

10.22038/nmj.2025.80411.1991

Abstract

Introduction: Several researchers have suggested using metal nanoparticles as an alternative to metal Bhasma—a traditional method of metal processing—to overcome the lengthy and time-consuming nature of Bhasmikaran. Therefore, it is crucial to compare the safety profiles of Rajat Bhasma (RB) and silver nanoparticles (AgNPs) synthesized through green methods.
Objective(s): This study compared the safety of Rajat Bhasma (RB) and silver nanoparticles (AgNPs) in a sub-chronic toxicity study.
Materials and Methods: In this study, 42 rats were divided into seven groups, each comprising six animals (three males and three females). Six groups were administered either Rajat Bhasma or silver nanoparticles orally for 28 days at therapeutically equivalent doses (TED) of 10.8 mg/kg, 10 × TED (108 mg/kg), and 20 × TED (216 mg/kg). Toxicity was evaluated based on general observations and hematological, biochemical, and histopathological assessments.
Results: The results demonstrated that Rajat Bhasma and silver nanoparticles administered at 10- and 20-fold TED doses adversely affected specific hematological parameters, including platelet count, mean corpuscular volume (MCV), and mean corpuscular hemoglobin (MCH) levels. Additionally, AgNPs induced alterations in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels, indicating hepatic toxicity, which was further corroborated by histopathological examination of the liver. Hydropic degeneration and congestion in the kidneys were observed in rats treated with RB at the 20 × TED dose and in all AgNP-treated groups.
Conclusion: RB and AgNPs were safe at therapeutically equivalent doses. However, AgNPs showed greater toxicity at higher doses compared to RB.

Keywords

References

  1. Kulkarni DA. Part I. Vidyan Bodhini Commentary on Rasa Ratna Samucchaya of Vagbhat. 5-13. 1st Edition, Ch.5,ver.13;1998: Meharchand Lachmandas Publications, New Delhi.93.
  2. Zha CB. Ayurvediya Rasashastra. Reprint. Ch.3;2010: Chaukhambha Surbharati Prakashan, Varaansi. 73.
  3. Kulkarni DA. Part I. Vidyan Bodhini Commentary on Rasa Ratna Samucchaya of Vagbhat. 1st Edition, Ch.5, ver.28-29;1998: Meharchand Lachmandas Publications, New Delhi. 97.
  4. Sharma S. Rasa Tarangini. Chapter 16, Verse 46-54;1998:Motilal Banarasidas; New Delhi, India. 394.
  5. Mohammadpour R, Dobrovolskaia MA, Cheney DL, Greish KF, Ghandehari H. Subchronic and Chronic Toxicity Evaluation of Inorganic Nanoparticles for Delivery Applications. Advanced Drug Delivery Reviews. 2019;144:112-132.
  6. Noga M, Milan J, Frydrych A, Jurowski K. Toxicological Aspects, Safety Assessment, and Green Toxicology of Silver Nanoparticles (AgNPs)— Critical Review: State of the Art. Int J Mol Sci. 2023;24(6): 5133.
  7. De Matteis V. Exposure to inorganic nanoparticles: routes of entry, immune response, biodistribution and in vitro/in vivo toxicity evaluation. Toxics. 2017;5(4):29.
  8. Vanlalveni C, Lallianrawna S, Biswas A, Selvaraj M, Changmai B, Rokhum SL. Green synthesis of silver nanoparticles using plant extracts and their antimicrobial activities: a review of recent literature. RSC Adv. 2021;11(5):2804-2837.
  9. Sarkar PK, Chaudhary AK. Bhasma: application of nanomedicine. Journal of Scientific & Industrial Research.2010; 69(12): 901-905.
  10. Pal D, Sahu CK, Haldar A. Bhasma : The ancient Indian nanomedicine. J Adv Pharm Technol Res. 2014;5(1):4-12.
  11. Paul S, Chaugh A. Assessing the Role of Ayurvedic ‘Bhasms’ as Ethno-nanomedicine in the Metal Based Nanomedicine Patent Regime. Journal of Intellectual Property Rights. 2011;16(11): 509-515.
  12. Umrani RD, Paknikar KM. Jasada bhasma, a Zinc-Based Ayurvedic Preparation: Contemporary Evidence of Antidiabetic Activity Inspires Development of a Nanomedicine. Evidence-Based Complementary and Alternative Medicine. 2015.
  13. Sreelakshmi S, Vineeth PK, Mohanan A, Ramesh NV. Ayurvedic bhasma and synthesized nanoparticles: A comparative review, Materials Today: Proceedings. 2021; 46(8):3079-3083.
  14. Nie P , Zhao Y,  Xu H. Synthesis, applications, toxicity and toxicity mechanisms of silver nanoparticles: A review. Ecotoxicology and Environmental Safety. 2023; 253:114636.
  15. Auclair J, Gagné F. Shape-dependent toxicity of silver nanoparticles on freshwater cnidarians. Nanomaterials (Basel). 2022;12(18):3107.
  16. Bhujbal SS, Kakde AG, Nanda RK, Darade SB, Dharmadhikari SS. Evaluation and acute toxicity studies of herbally prepared silver nanoparticles and Rajat Bhasma using modern analytical instruments. Inter J Green Pharm. 2021;15 (2):201-207.
  17. Shastri K, editor. Rasatarangini. Chapter 15, verse 4-6;1998: Motilal Banarasidas, New Delhi.362.
  18. Shastri K, editor. Rasatarangini.Chapter 16, verse 6;1998: Motilal Banarasidas, New Delhi.387.
  19. Shastri K, editor.Rasatarangini. Chapter16, verse 26-28,1998: Motilal Banarasidas, New Delhi.391.
  20. Fursule D, Gandhi P. A Dissertation submitted to the Maharashtra University of health Sciences, Nashik, Maharashtra.2020.
  21. OECD, Test No.407: repeated dose 28-day oral toxicity study in rodents, OECD Guidelines for the Testing of Chemicals;2008:Organization for Economic Cooperation and Development, Paris, France.
  22. Kpemissi M, Metowogo K, Melila M, Veerapur VP, Negru M, Taulescu M, et.al. Acute and subchronic oral toxicity assessments of Combretum micranthum (Combretaceae) in Wistar rats. Toxicol Rep. 2020;1(7):162-168.
  23. Liu C, Liu J, Zheng Y, Qu J, Yang W, Tang X, et.al. Subchronic oral toxicity study of rhubarb extract in Sprague-Dawley rats. Regul Toxicol Pharm. 2021:123.
  24. Agyigra A, Ejiofor JI, Magaji MG. Acute and subchronic toxicity evaluation of methanol stem-bark extract of Ximeniaamericana Linn (Olacaceae) in Wistar rats. Bull Faculty Pharm Cairo Univ.2017;55 (2):263–267.
  25. Culling, C.F.A.Handbook of Histopathological and Histochemical Techniques. 3rd edition;1974: Butterworths, London.
  26. Patole VC, Awari D, Chaudhari S. Resveratrol-Loaded Microsponge Gel for Wound Healing: In Vitroand In Vivo Turk J Pharm Sci. 2023;20(1):23-34.
  27. Alexander JW. History of the medical use of silver.Surg Infect. (Larchmt). 2009;10 (3): 289–292.
  28. Drake PL, Hazelwood KJ. Exposure-related health effects of silver and silver compounds: a review. Ann Occup Hyg. 2005; 49(7): 575–585.
  29. Scroggs MW, Lewis JS, Proia AD. Corneal argyrosis associated with silver soldering, Cornea. 1992; 11 (3): 264–269.
  30. Fuller FW, Engler PE. Leukopenia in non-septic burn patients receiving topical 1% silver sulfadiazine cream therapy: a survey. J Burn Care Rehabil. 1988; 9 (6):606–609.
  31. Ebabe Elle R, Gaillet S, Vidé J, Romain C, Lauret C, Rugani N, Cristol JP, Rouanet JM. Dietary exposure to silver nanoparticles in Sprague-Dawley rats: effects on oxidative stress and inflammation. Food Chem Toxicol. 2013;60: 297-301.
  32. Stepien KM, Morris R, Brown S, Taylor A, Morgan L. Unintentional silver intoxication following self-medication: an unusual case of corticobasal degeneration. Ann Clin Biochem. 2009; 46 (6):520–522.
  33. Ohbo Y, Fukuzako H, Takeuchi K, Takigawa M. Argyria and convulsive seizures caused by ingestion of silver in a patient with schizophrenia. Psychiatry Clin Neurosci.1996; 50 (2):89–90.
  34. Hadrup N, Lam HR. Oral toxicity of silver ions, silver nanoparticles and colloidal silver: a review. Regul Toxicol Pharmacol. 2014;68 (1):1–7.
  35. Rasaratnasamuccaya.Meharchand Lachhmandas Pub, New Delhi, India.97. 1998; 5(30).
  36. Egbuna C, Parmar VK, Jeevanandam J, Ezzat SM, Patrick-Iwuanyanwu KC, Adetunji CO, et al. Toxicity of Nanoparticles in Biomedical Application: Nanotoxicol J Toxicol. 2021;30.
  37. Stensberg MC, Wei Q, McLamore ES, Porterfield DM, Wei A, Sepúlveda MS. Toxicological studies on silver nanoparticles: challenges and opportunities in assessment, monitoring and imaging. Nanomedicine (Lond). 2011 Jul;6(5):879-98.
  38. Zhang J, Wang F, Yalamarty SSK, Filipczak N, Yi Jin , Xiang Li. Nano Silver-Induced Toxicity and Associated Mechanisms. Inter J Nanomed. 2022; 17(4): 1851-1864.
  39. Mukkavallia S, Chalivendrab V, Singh B R. Physico-chemical analysis of herbally prepared silver nanoparticles and its potential as a drug bioenhancer. Open Nano.2017;2:19–27.
  40. Timbrell JA. Principles of Biochemical Toxicology;1982: Taylor and Francis Limited, London.446.
  41. Kim YS, Song MY, Park JD, Song KS, Ryu HR, et al. Subchronic oral toxicity of silver nanoparticles. Particle Fibre Toxicol. 2010; 7(1):1-11.
  42. Agency for Toxic Substances and Disease Registry (ATSDR), Toxicological Profile for Silver; 1990: US Department of Health and Human Services, Atlanta, GA.
  43. Hultman P, Eneström S,Turley SJ, Pollard KM. Selective induction of anti-fibrillarin autoantibodies by silver nitrate in mice. Clin Exp Immunol.1994;96 (2): 285–291.
  44. Ilyechova EY, Puchkova LV, Shavlovskii MM, Korzhevskii DE,Petrova ES,Tsymbalenko NV. Effect of silver ions on copper metabolism during mammalian ontogenesis. Russ J Dev Biol.2018;49 (3):166–178.

 

Nanomedicine Journal

Articles in Press, Accepted Manuscript
Available Online from 23 June 2025

Files

Share

How to cite

Statistics